NTRA Latest Press Releases

-- October 18, 2026 --

ESMO 2026 Presentations Deepen the Evidence Base for Natera's Oncology Portfolio and Leadership in Ultrasensitive MRD Technology Business Wire 6:10 PM

-- October 15, 2026 --

Natera's Signatera MRD Test Named to TIME's List of the Best Inventions of 2026 Business Wire 12:46 PM

-- October 13, 2026 --

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer Business Wire 7:30 AM

-- October 9, 2026 --

FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay Business Wire 8:00 AM

-- October 7, 2026 --

Natera Announces Randomized, Signatera -Guided Interventional Study in Melanoma Business Wire 8:00 AM

-- October 6, 2026 --

New Signatera Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists Business Wire 8:00 AM

-- October 5, 2026 --

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer Business Wire 8:00 AM

-- September 22, 2026 --

Signatera Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer Business Wire 8:00 AM

-- September 18, 2026 --

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM Business Wire 6:00 AM

-- September 1, 2026 --

New Publication Establishes Strong Clinical Validation of Signatera for MRD Assessment in Lymphoma Business Wire 6:00 AM

-- August 28, 2026 --

Natera and Susan G. Komen Announce National Partnership to Accelerate Progress Against Breast Cancer Business Wire 11:03 AM

-- August 27, 2026 --

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate Using Signatera Business Wire 6:00 AM

-- August 12, 2026 --

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude in Advanced Skin Cancers Business Wire 6:00 AM

-- August 6, 2026 --

Natera Reports Second Quarter 2026 Financial Results Business Wire 4:05 PM

-- August 5, 2026 --

Natera Submits Signatera to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer Business Wire 6:00 AM

-- July 30, 2026 --

Natera to Report its Second Quarter Results on August 6, 2026 Business Wire 8:00 AM

-- July 22, 2026 --

Signatera MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study Business Wire 6:00 AM

-- July 16, 2026 --

Finalized MolDx LCD Includes Expanded Coverage for Natera's Prospera Portfolio Business Wire 6:35 PM

-- July 9, 2026 --

Natera Announces IVDR Certification for Signatera Across Multiple Cancers Business Wire 6:00 AM

-- July 6, 2026 --

Signatera MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer Business Wire 6:00 AM

-- June 29, 2026 --

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer Business Wire 6:00 AM

-- June 25, 2026 --

Natera and Eledon Announce Strategic Partnership for Prospera Monitoring in Planned Phase 3 Kidney Transplant Trial Business Wire 7:00 AM

-- June 24, 2026 --

Signatera Receives Regulatory Approval in Japan for Colorectal Cancer Business Wire 3:00 AM

-- June 23, 2026 --

NCCN Recommends ctDNA-MRD Testing Using Signatera Technology in Landmark Bladder Cancer Guideline Update Business Wire 6:00 AM

-- June 18, 2026 --

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress Business Wire 6:00 AM

-- June 4, 2026 --

Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer Business Wire 8:00 AM

-- June 3, 2026 --

Natera Appoints Oncology Leaders Drs. Thomas Lynch and Eric Rubin to Board of Directors Business Wire 8:00 AM

-- May 29, 2026 --

Natera Announces Collaboration with Diakonos Oncology for Signatera in Refractory Melanoma Business Wire 6:00 AM

-- May 28, 2026 --

Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer Business Wire 6:00 AM

-- May 26, 2026 --

Natera to Launch Enhanced Panorama NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology Business Wire 6:00 AM

-- May 21, 2026 --

Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology Business Wire 5:05 PM

Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World Business Wire 7:00 AM

-- May 20, 2026 --

EXPAND Trial of Natera's Fetal Focus Single-Gene NIPT Surpasses >2,000 Patients Enrolled Business Wire 7:00 AM